AMGN vs. REGN: Amgen vs. Regeneron Pharmaceuticals Stock Comparison
How do Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Amgen (AMGN) and Regeneron Pharmaceuticals (REGN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | AMGN | REGN |
|---|---|---|
| Name | Amgen Inc. Common Stock | Regeneron Pharmaceuticals, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 249.05 billion USD | 93.55 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 17, 1983 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AMGN | REGN |
|---|---|---|
| Total Return (1Y) | 48.82% | 40.87% |
| Total Return (3Y, Annualized) | 24.31% | 5.15% |
| Total Return (5Y, Annualized) | 20.67% | 8.58% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AMGN | REGN |
|---|---|---|
| Volatility (1Y, Annualized) | 29.12% | 34.08% |
| Beta (5Y) | 0.43 | 0.10 |
| Max Drawdown (5Y) | -24.86% | -59.69% |
| Avg. Volume (3M) | 2.76M | 772.95K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AMGN | REGN |
|---|---|---|
| Sharpe Ratio (1Y) | 1.53 | 1.07 |
| Sortino Ratio (1Y) | 2.36 | 1.70 |
Profitability
ROE (TTM)
Both Amgen (AMGN) at 78.35% and Regeneron Pharmaceuticals (REGN) at 14.95% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
78.35%
- Max
- 109.18%
- AMGN
- 78.35%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.95%
- Max
- 109.18%
- REGN
- 14.95%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Amgen (AMGN) at 24.14% and Regeneron Pharmaceuticals (REGN) at 28.51% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.14%
- AMGN
- 24.14%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.51%
- REGN
- 28.51%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Amgen (AMGN) at 35.79% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.79%
- Max
- 83.12%
- AMGN
- 35.79%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.46%
- Max
- 83.12%
- REGN
- 40.46%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AMGN | REGN |
|---|---|---|
| ROE (TTM) | 78.35% | 14.95% |
| ROA (TTM) | 8.91% | 7.59% |
| Net Margin (TTM) | 24.14% | 28.51% |
| Operating Margin (TTM) | 35.79% | 40.46% |
| Gross Margin (TTM) | 72.47% | 46.73% |
Growth
Revenue Growth
Both Amgen (AMGN) at 9.95% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Regeneron Pharmaceuticals (REGN) at 8.19% is closer to the peer norm — faster per-share earnings growth for AMGN.
Growth Metrics
| Metric | AMGN | REGN |
|---|---|---|
| Revenue Growth (YoY) | 9.95% | 0.99% |
| Revenue Growth (3Y CAGR) | 11.77% | 5.62% |
| EPS Growth (YoY) | 88.23% | 8.19% |
| EPS Growth (3Y CAGR) | 5.52% | 2.77% |
Financial Strength
Current Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AMGN
- 1.48
- Min
- 0.10
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- REGN
- 3.35
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Regeneron Pharmaceuticals (REGN) at 0.08 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.76
- AMGN
- 3.76
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.08
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- REGN
- 0.08
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AMGN | REGN |
|---|---|---|
| Current Ratio (MRQ) | 1.48 | 3.35 |
| Debt / Equity (MRQ) | 3.76 | 0.08 |
| Net Debt / EBITDA | 2.31 | -1.17 |
Dividends
Dividend Yield (TTM)
Both Amgen (AMGN) at 2.16% and Regeneron Pharmaceuticals (REGN) at 0.41% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.16%
- AMGN
- 2.16%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41%
- REGN
- 0.41%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Amgen (AMGN) at 57.62% and Regeneron Pharmaceuticals (REGN) at 8.18% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.62%
- AMGN
- 57.62%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.18%
- REGN
- 8.18%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AMGN | REGN |
|---|---|---|
| Dividend Yield (TTM) | 2.16% | 0.41% |
| Dividend Payout Ratio (TTM) | 57.62% | 8.18% |
Valuation
P/E Ratio (TTM)
Both Amgen (AMGN) at 26.69 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.69
- Max
- 85.34
- Q3
- 43.46
- AMGN
- 26.69
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.99
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- REGN
- 19.99
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Amgen (AMGN) at 6.40 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AMGN
- 6.40
- Q1
- 3.01
- Min
- 0.01
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.54
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- REGN
- 5.54
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 2.71 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.35
- AMGN
- 17.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- REGN
- 2.71
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AMGN | REGN |
|---|---|---|
| P/E Ratio (TTM) | 26.69 | 19.99 |
| P/S Ratio (TTM) | 6.40 | 5.54 |
| P/B Ratio (MRQ) | 17.35 | 2.71 |
| Free Cash Flow Yield (TTM) | 2.96% | 2.76% |